Chrysalis BioTherapeutics
Laurie has over 15 years experience in directing laboratory operations, quality data system management, and prior experience with TP508. Her prior research at the University of Texas Medical Branch demonstrated a unique TP508 (Chrysalin) receptor-mediated signaling cascade involved in tissue repair. Laurie has been the Principle Investigator (PI/PD) on several of the company’s SBIR grants and contracts and directs all Non-Clinical Regulated Studies for Chrysalis BioTherapeutics.
Chrysalis BioTherapeutics
Chrysalis BioTherapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of treatments for serious respiratory disorders and acute radiation exposure.